Eligibility for Semaglutide 2.4 mg in US Adults with Obesity and Prediabetes, Based on the STEP-10 Trial Criteria

被引：0
|
作者：
Chetty, Ashwin K.
Khunte, Mihir
Lu, Yuan
Chen, Alissa S.
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] Brown Univ, Warren Alpert Med Sch, Providence, RI USA
[3] Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT USA
[4] Yale Sch Med, Dept Internal Med, Natl Clinician Scholars Program, New Haven, CT USA
来源：
AMERICAN HEART JOURNAL | 2024年 / 278卷
关键词：
obesity; prediabetes; semaglutide;
D O I：
10.1016/j.ahj.2024.09.026
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0057
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Semaglutide 2.4mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity
    Garvey, T. W.
    Holst-Hansen, T.
    Laursen, P. N.
    Rinnov, A. R.
    Wilkinson, L.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S287 - S287
  • [42] THE COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4MG IN PATIENTS WITH OVERWEIGHT/OBESITY AND CARDIOVASCULAR DISEASE FROM THE SELECT TRIAL
    McEwan, P.
    Bog, M.
    Faurby, M.
    Foos, V
    Lingvay, I
    Lubker, C.
    Miller, R.
    Toliver, J.
    Yeates, F.
    Lincoff, A. M.
    VALUE IN HEALTH, 2024, 27 (06) : S148 - S148
  • [43] Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity
    Garvey, W. Timothy
    Holst-Hansen, Thomas
    Laursen, Peter N.
    Rinnov, Anders R.
    Wilkinson, Lua J.
    DIABETES, 2022, 71
  • [44] Eligibility for Semaglutide in US Adults with Diabetes and Potentially Preventable Cardiovascular Events Projected from the SUSTAIN-6 Trial
    Wong, Nathan
    Karthikeyan, Hridhay
    Fan, Wenjun
    CIRCULATION, 2024, 150
  • [45] Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial
    Snitker, Soren
    Egebjerg, Christina
    Frederiksen, Marie
    Sparre, Thomas
    DIABETES OBESITY & METABOLISM, 2022, 24 (11): : 2273 - 2276
  • [46] Protocol for a randomised, double-blinded, controlled trial of youth with childhood-onset obesity treated with semaglutide 2.4 mg/week: the RESETTLE trial
    Byberg, Sarah
    Holt, Joachim
    Sandsdal, Rasmus Michael
    Holm, Louise Aas
    Madsen, Laerke Bruun
    Christensen, Bodil Just
    Jensen, Simon Birk Kjaer
    Hansen, Torben
    Holm, Jens-Christian
    Torekov, Signe
    BMJ OPEN, 2024, 14 (11):
  • [47] Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial
    le Roux, C.
    Lau, D. C. W.
    Astrup, A.
    Fujioka, K.
    Greenway, F.
    Halpern, A.
    Krempf, M.
    Violante Ortiz, R.
    Wilding, J. P. H.
    Jensen, C. B.
    Svendsen, C. B.
    Pi-Sunyer, X.
    DIABETOLOGIA, 2014, 57 : S338 - S338
  • [48] Treatment with once-weekly semaglutide 2.4 mg improves cardiometabolic risk factors in adults with overweight or obesity and type 2 diabetes: STEP 2 post-hoc analysis
    Deanfield, J. E.
    Davies, M.
    Garvey, W. T.
    Jeppesen, O. K.
    Khalid, U.
    Kosiborod, M.
    Kushner, R. F.
    Laursen, P. N.
    Rubino, D. M.
    Verma, S.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 249 - 249
  • [49] The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials
    Bjorner, Jakob Bue
    Larsen, Sara
    Lubker, Christopher
    Holst-Hansen, Thomas
    DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2142 - 2150
  • [50] Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis
    Kushner, Robert F.
    Davies, Melanie J.
    Deanfield, John
    Garvey, W. Timothy
    Jeppesen, Ole
    Khalid, Usman
    Kosiborod, Mikhail N.
    Laursen, Peter N.
    Rubino, Domenica
    Verma, Subodh
    DIABETES, 2021, 70
12345